Please login to the form below

Not currently logged in
Email:
Password:

sodium zirconium cyclosilicate

This page shows the latest sodium zirconium cyclosilicate news and features for those working in and with pharma, biotech and healthcare.

Real-world data finds patients feel better on Entresto, says Novartis

Real-world data finds patients feel better on Entresto, says Novartis

Lokelma (sodium zirconium cyclosilicate or ZS-9) and Vifor Pharma’s Veltassa (patiromer) which “will be a particularly valuable addition to the clinic if efficacy can be confirmed in clinical trials”.

Latest news

  • AZ gets US approval for Veltassa rival Lokelma AZ gets US approval for Veltassa rival Lokelma

    Lokelma (sodium zirconium cyclosilicate or ZS-9) has been cleared by the FDA as an oral treatment for hyperkalaemia (elevated potassium levels) in adults, a potentially life-threatening condition caused by

  • AZ finally gets EU nod for Veltassa rival Lokelma AZ finally gets EU nod for Veltassa rival Lokelma

    Lokelma (sodium zirconium cyclosilicate or ZS-9) has been approved for adults with hyperkalaemia, a potentially life-threatening condition which can cause cardiac arrest and muscle paralysis, allowing it to finally

  • Vifor wins European approval for Veltassa Vifor wins European approval for Veltassa

    However, there’s potential competition on the horizon from AstraZeneca, which has a positive opinion the Committee for Medicinal Products for Human Use (CHMP) for its hyperkalaemia drug Lokelma (sodium zirconium ... cyclosilicate) in February.

  • FDA turns down AZ's ZS-9 once again on manufacturing issues FDA turns down AZ's ZS-9 once again on manufacturing issues

    The US regulator issued a Complete Response Letter to ZS Pharma regarding its application for ZS-9 (sodium zirconium cyclosilicate) as a treatment for the condition - known as hyperkalaemia - after an

  • AZ nears EU approval for hyperkalaemia drug Lokelma AZ nears EU approval for hyperkalaemia drug Lokelma

    Lokelma (sodium zirconium cyclosilicate) is a potassium-binding compound designed to reduce excessive levels of serum potassium by drawing it into the gastrointestinal tract.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics